Director of Drug Development, Sarah Cannon Research Institute at Florida Cancer Specialists, Lake Nona @SarahCannonDocs #hncsm #HeadandNeckCancer
Joined December 2011
- Tweets 17
- Following 42
- Followers 57
- Likes 106
Photos and videos
Cesar retweeted
18 Sep 2025
The FDA has granted FTD to CRB-701, a next-generation ADC targeting nectin-4, for patients with recurrent or metastatic HNSCC previously treated with platinum-based chemotherapy and an anti-PD(L)1 therapy.
hubs.li/Q03JRtl90
#hncsm #oncology #cancer
1
1
267
Cesar retweeted
4 Jun 2024
Dr. Cesar Perez presenting at the educational session on Head and neck cancers at ASCO 2024 #ASCO24
5
12
1,427
Cesar retweeted
24 Oct 2023
Recommendations for Global Curriculum in #MedicalOncology: result of great collaboration btw @myesmo & @ASCO and the full support of @JCOGO_ASCO & @ESMO_Open
23 Oct 2023
The 2023 edition of the ESMO/ASCO Recommendations for a Global Curriculum in Medical Oncology is out! Read the paper in @ESMO_Open
📌 ow.ly/nhpq50PZztv
2
13
45
22,407
28 Jul 2023
RT @Latinamd: Si la montaña no va a Mahoma, Mahoma va a la montaña. ( If the mountain does not come to Mohammed…)
Visiting our former @Sy…
2
Cesar retweeted
2 Jun 2023
1
3
6
454
Cesar retweeted
14 Nov 2022
.@US_FDA granted a fast track designation to KIN-2787 in patients with BRAF class II or III alteration–positive and/or NRAS mutation–positive, metastatic or unresectable, stage IIB to IV malignant melanoma. @CesarAPerezMD @SarahCannonDocs #melcsm
ow.ly/S58P50LtLgL
3
1
Cesar retweeted
24 Sep 2021
It's World Cancer Research Day and Dr. Cesar Perez, Director of Drug Development at Sarah Cannon Research Institute at Florida Cancer Specialists - Lake Nona, is sharing his wisdom on the importance of clinical trials in the life of patients facing cancer. #WorldCancerResearchDay
3
3
Cesar retweeted
5 Aug 2021
In the phase III JUPITER-02 trial, addition of the anti-PD-1 antibody toripalimab to first-line gemcitabine plus cisplatin for pts with advanced-stage nasopharyngeal carcinoma improved PFS 11.7 vs 8.2 months and also OS (HR 0.61, P = 0.046): nature.com/articles/s41591-0… #hncsm
2
5
Cesar retweeted
4 Jul 2021
According to data from a landmark phase 3 trial, in the ITT population of patients with advanced primary SCCHN, the Multikine treatment regimen yielded an OS benefit of 14.1%. #hncsm ow.ly/HoEg50FlLAw
1
2
Cesar retweeted
7 Jul 2021
Cabozantinib demonstrates efficacy in radioactive-iodine and VEGFR refractory patients. Another option for thyroid cancer patients but keep in mind the importance of molecular testing to find actionable alterations in NTRK, RET, and BRAF.
thelancet.com/journals/lanon…
7
23
#ASCO21 Press Release: JUPITER-02 Trial- Toripalimab plus standard first-line chemo significantly delayed disease progression for pts w recurrent or metastatic nasopharyngeal carcinoma fal.cn/3fQ5G #hncsm #immunoonc
7
9